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AbstrAct
Strategies to prevent organ transplant rejection whilst minimizing long-term 
immunosuppression are currently under intense investigation with regulatory T cells 
(Tregs) nearing clinical application. The clinical trial, ThRIL, recently commenced 
at King’s College London, proposes to use Treg cell therapy to induce tolerance in 
liver transplant recipients, the success of which has the potential to revolutionize 
the management of these patients and enable a future of drug-free transplants. This 
is the first report of the manufacture of clinical grade Tregs from prospective liver 
transplant recipients via a CliniMACS-based GMP isolation technique and expanded 
using anti-CD3/CD28 beads, IL-2 and rapamycin. We report the enrichment of a pure, 
stable population of Tregs (>95% CD4+CD25+FOXP3+), reaching adequate numbers 
for their clinical application. Our protocol proved successful in, influencing the 
expansion of superior functional Tregs, as compared to freshly isolated cells, whilst 
also preventing their conversion to Th17 cells under pro-inflammatory conditions. We 
conclude with the manufacture of the final Treg product in the clinical research facility 
(CRF), a prerequisite for the clinical application of these cells. The data presented in 
this manuscript together with the much-anticipated clinical results from ThRIL, will 
undoubtedly inform the improved management of the liver transplant recipient.
IntroductIon
Liver transplantation remains the treatment 
of choice for patients with end stage liver disease. 
Therapeutic advances in immunosuppression have led to 
a dramatic improvement in allotransplantation, averting 
acute rejection and supporting short-term graft survival. 
However, the obligatory protracted use of powerful non-
specific immunosuppressants is complicated by increased 
morbidity and mortality as a result of chronic rejection and 
associated toxicity. The constant proportion of transplanted 
organs lost each year necessitating re-transplantation, in a 
climate of donor organ shortage, places further strain on 
an already saturated transplant waiting list.
The current approach to immunosuppression in 
transplantation is far from ideal with an enormous interest 
in the minimization/complete withdrawal of these drugs 
in liver transplant recipients. There have also been reports 
of a variable proportion of liver transplant recipients 
developing a state of ‘operational’ tolerance thus forgoing 
the requirements of therapeutic immunosuppression 
[1]. This phenomenon, however, only occurs late after 
transplantation and in a minority of patients [2]. It is, 
therefore, necessary to find novel strategies to allow for 
the development of tolerance early after transplantation 
and in turn negate the use of lifelong immunosuppression. 
In this setting regulatory T cells (Tregs) are 
attractive candidates for therapeutic strategies aimed at 
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tolerance induction, bearing in mind their integral role in 
promoting immune homeostasis. Characterised by the high 
and stable expression of surface interleukin-2 receptor 
α chain (IL-2Rα, CD25hi) and the transcription factor, 
FOXP3, these cells only constitute approximately 1-3% 
of circulating CD4+ T cells in the periphery [3-5]. As such, 
recent advances permitting the expansion of these cells 
ex vivo presents an attractive opportunity in modulating 
immune responses through their adoptive transfer. We 
have shown that infusion of recipient murine Tregs, 
expanded in vitro, can prolong skin allograft survival and 
induce indefinite acceptance of heart allografts [6]. More 
recently, the adoptive transfer of polyclonal human Tregs 
in humanised mice protected from human skin pathology 
and induced increased survival of transplanted islets [7-9]. 
The posited implications of Treg cell therapy in the 
context of liver transplantation have been aptly construed 
in murine models whereby liver allografts from tolerant 
mice were infiltrated with Tregs, and the depletion of 
these cells resulted in a loss of tolerance [10]. This 
circumstance is further mirrored in human subjects with 
increased frequencies of Tregs reported in operationally 
tolerant liver transplant recipients [11] paralleled by low 
circulating levels during acute rejection [12]. As such, 
there is little doubt that Tregs are promising candidates 
for tolerance induction in liver transplantation.
To date no clinical trials addressing the safety and 
efficacy of Treg cell therapy in the induction of tolerance 
in solid organ transplantation have been described. Recent 
trials have primarily focused on the safety profile of Treg 
therapy in the setting of bone marrow transplantation [13-
15] and type I diabetes [16], with encouraging reports 
of efficacy. As a result, the prospects of applying Treg 
adoptive cell therapy in organ transplantation are now 
widely recognised.
In this regard, we have just opened the first combined 
Phase I/IIa clinical trial of Treg immunotherapy in the 
setting of liver transplantation, ThRIL (NCT02166177). 
Here, the safety, tolerability and efficacy of polyclonally 
expanded autologous Tregs from patients with end-stage 
liver disease, in combination with thymoglobulin and an 
mTOR-inhibitor-based immunosuppression regimen, will 
be assessed.
This is the first report, employing a Good 
Manufacturing Practice (GMP)-compliant protocol for 
the ex vivo expansion of Tregs from prospective liver 
transplant recipients. We further present the successful 
manufacture of the final drug product in the Biomedical 
Research Centre Clinical Research Facility (BRC CRF) 
at Guy’s Hospital (King’s College London) as a prelude 
for ThRIL. 
results
Isolation and expansion of a pure treg population 
from Arc patients
In preparation for ThRIL, clinical grade autologous 
Tregs were isolated from 9 patients with alcohol related 
cirrhosis (ARC), awaiting transplantation, and 9 age and 
sex matched healthy controls (HCs). Using a protocol 
previously reported [17], similar numbers of cells were 
isolated from ARC patients and HCs (7.14x106 ± 0.938 
vs. 7.91x106 ± 0.728, respectively; P = 0.528) (Figure 
1A). This result confirms the similar frequency of Tregs 
observed ex vivo in the blood of ARC patients and HCs 
(4.13 ± 0.932 compared with 4.31 ± 0.889, respectively; P 
= 0.888) (Figure 1B). 
The feasibility of autologous T cell therapy depends 
on success in the expansion of sufficient cell numbers in 
vitro. In this regard, Tregs were expanded using anti-CD3/
CD28 monoclonal antibody-coated beads, high dose IL-2 
and rapamycin, as previously reported [17, 18]. 
Assessment of the percentages of cells expressing 
CD8+, CD4+ and CD25+ molecules, demonstrated on 
average a purity of 77.7% ± 10.3 CD4+CD25+ and 2.50 
% ± 1.71 CD8+ cells at the start of the culture (S1). 
Expansion in vitro under the conditions described led to 
an enrichment of CD4+CD25+ cells; 91.3% ± 2.33, P = 
0.004 with only 0.153% ± 0.073; P = 0.008 CD8+ cells 
at the end of culture (Figure 2A, 2B). The comparable 
purities of cells cultured in the absence of rapamycin were 
87.5% ± 4.12; P = 0.088 and 0.292% ± 0.172; P = 0.0019, 
respectively. 
In line with previous reports [19] the mean 
fluorescent intensity (MFI) of CD25 expression was 
highest following exposure of Tregs to rapamycin (data 
not shown). 
tregs from Arc patients can be expanded to 
clinically suitable numbers
We next determined whether patient-derived Tregs 
could be expanded in vitro to numbers required for the 
maximum dose of Treg injection planned for ThRIL 
(4.5x106/Kg).
Tregs from both patients and HCs expanded rapidly 
with comparable fold-expansion during the 36 days of 
culture (in the presence of rapamycin: ARC 1430 ± 239 vs 
HC 1060 ± 139; P = 0.207, in the absence of rapamycin: 
ARC 2080 ± 428 vs HC 1670 ± 359; P = 0.469) (Figure 
2C). In addition, despite a trend for a reduced fold 
expansion there was no statistical difference in fold-
expansion of Treg lines in the presence of rapamycin as 
compared to untreated cultures for both cohorts (ARC; 0 
.199, HC; P = 0.135). Additionally the average expansion 
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of the 9 different Treg lines in the presence of rapamycin 
was 1.07 x 109 cells ± 0.085 (Figure 2D), demonstrating 
the feasibility of reaching numbers needed for the high 
dose of Tregs planned to be administered in ThRIL. 
rapamycin expanded tregs maintained high 
levels of FoXP3, cd127lo and ctlA4 with a 
sustained expression of cd62l and cXcr3
Having established the enrichment of CD4+CD25+ 
Tregs under these culture conditions, the expression of 
the transcription factor, FOXP3, of importance in Treg 
development and function was analysed [20]. Initially, 
upon isolation the total percentage of CD4+CD25+FOXP3+ 
cells stood at 77.7% ± 3.35, and contrary to published 
data reporting a loss of FOXP3 expression with prolonged 
periods of culture [21], the data reported an increase in the 
purity of culture in the presence of rapamycin to 90.66% 
± 2.19, P =0.0053. (Figure 3A).
In addition, using a more stringent gating strategy 
whereby we were able to distinguish two distinct 
populations based on FOXP3 expression, termed FOXP3Hi 
and FOXP3Int (Supplementary Figure 1) it was also 
shown that the percentage of CD4+CD25+FOXP3Hi cells 
was increased in culture in the presence of rapamycin 
(S1: 24.7% ± 2.95 vs. Final harvest: 63.4% ± 4.23; P < 
0.0001) as compared to the untreated cultures (Figure 3B). 
In agreement, the MFI of FOXP3 was higher following 
exposure to rapamycin as compared to untreated cultures 
and baseline (Figure 3C). 
Additionally, several subsets of Tregs have been 
described to date with reports that CD4+CD25hi FOXP3+ 
Tregs typically lack the expression of the interleukin 
(IL)-7 receptor alpha chain, CD127 [22]. The differential 
expression of CD127 has been used to denote an optimally 
pure population of Tregs that is inversely correlated 
with FOXP3 levels and the suppressive function of 
human CD4+ Tregs. In support of the increase in purity 
of the cultures in the presence of rapamycin, our data 
demonstrate an increase in the frequency of CD127lo in 
the rapamycin treated cultures as compared the untreated 
cultures (P = <0.0001) (Figure 3D).
Constitutive high level of expression of CTLA-4 
represents another well-documented trait of Tregs that has 
also been shown to contribute to their suppressive function 
[23-25]. Analysis of the cultures at final harvest revealed 
that rapamycin led to an increase in the percentage of 
Figure 1: GMP treg Isolation. A. Numbers of cells isolated from 150ml of blood by CD8+ cell depletion and CD25+ cell enrichment 
compared between 9 ARC patients and 9 HCs. ***P < 0.001. b. Representative dot plot and graph denoting the circulating percentage of 
CD4+CD25Hi Tregs of 5 ARC patients and 5 HCs. Abbreviation: n.s- not significant. Data are represented as mean +/- SEM.
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Tregs expressing CTLA-4 (S1: 15.3% ± 2.51 vs Final 
harvest: 70.6% ± 4.522; P < 0.0001) as compared to 
untreated cells (Final harvest: 14.6 ± 4.15; P = 0.859) 
(Figure 3F) and this was mirrored by an increase in the 
MFI of this marker in rapamycin treated cultures as 
compared to baseline (Figure 3G). 
An additional consideration regarding Treg therapy 
is the site of action of Tregs and, consequently, the desired 
Figure 2: GMP compatible treg isolation and expansion. Two step strategy for Treg isolation: A. CD8+ cell depletion. b. 
CD25+ cell enrichment. In each case dots plots are representative of 9 ARC patients. Graphs denote the purity of the culture throughout 
the expansion period in both rapamycin and untreated cultures c. Tregs from ARC patients and HCs were expanded over 36 days ± 
rapamycin. Fold expansion was calculated from Treg numbers at each stimulation. d. Predicted Treg numbers over the 36 day expansion 
period calculated based on fold expansion and the assumption that all cells were expanded at each stimulation. n = 9 ARC, n = 9HCs. 
Abbreviation: S, stimulation; S1, day 0; S2, day 12; S3, day 24; final, day 36; n.s, not significant. **P < 0.05, ***P < 0.001. Data are 
represented as mean +/- SEM.
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homing properties of the injected cells. In the transplant 
setting, Treg lymph node homing and their ability to traffic 
to the graft are both required for their protection against 
graft rejection [26]. In this regard, it was shown that 
culture of Tregs in the presence of rapamycin maintained 
their expression of the lymphoid homing receptor, CD62L 
(S1: 68.1% ± 3.00 vs. Final harvest: 72.0% ± 3.51; P = 
0.412), which was not preserved when cells were cultured 
in the absence of rapamycin; P < 0.0001 (Figure 3H).
Furthermore, the expression of CXCR3, the 
chemokine receptor important for the migration and 
recruitment of Tregs to the liver was measured [27] at 
baseline and after the 36 days expansion. In the absence of 
rapamycin a decrease in the Tregs expressing CXCR3 P = 
0.015 was observed. In contrast, the addition of rapamycin 
maintained the expression of this marker on the Tregs 
(Figure 3H). Further analysis detailing the chemokine 
receptor expression of the final product and the cytokine 
production of the Tregs is presented in Supplementary 
Figures 2 and 3.
Ex vivo expanded tregs from Arc patients have 
increased suppressive ability
To assess the functional properties of Tregs CFSE 
dilution assays were performed to evaluate the ability of 
freshly isolated and ex vivo expanded Tregs from patients 
Figure 3: expression of regulatory markers and homing receptor expression by tregs throughout culture. A. Graph 
shows the mean percentage of CD4+CD25+ cells expressing FOXP3+ in both untreated and rapamycin treated cultures over 36 days of 
culture (n = 9 ARC). b. Graph shows the frequency of FOXP3Hi Tregs, from 9 ARC patients, throughout culture ± rapamycin. c. MFI of 
FOXP3 expression by Tregs. d. Graph shows the frequency CD127lo Tregs, from 9 ARC patients, throughout culture ± rapamycin. e. Dot 
plot details the frequency of CTLA-4 expression on CD4+CD25+ Tregs from one representative sample. F. The graph depicts the frequency 
of CD4+CD25+CTLA-4+ Tregs throughout culture ± rapamycin. G. MFI of CTLA-4 expression at S1 and day 36 of culture ± rapamycin. 
H. Expression of CD62L and CXCR3 on CD4+CD25+ on day 0 and at day 36 Tregs cultured ± rapamycin. Abbreviations: Mean fluorescent 
intensity (MFI) S- stimulation, n.s.-not significant. **P < 0.01, ***P < 0.001. Data are represented as mean +/- SEM. n = 9 ARC. 
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to suppress the proliferation of T effectors (Figure 4). 
The data clearly demonstrated that at the end of 
expansion, the suppressive function elicited by ARC 
Tregs in the presence of rapamycin was significantly 
higher as compared to freshly isolated Tregs at different 
Treg:Teffector ratios (1:1 ratio - final harvest: 84.8% ± 
3.96 vs. S1: 25.4% ± 6.03; P = 0 .0001, 1:10 ratio -final 
harvest: 68.3% ± 6.85 vs. S1: 16.2% ± 4.68; P = 0.0001). 
In the untreated cultures, despite an increase in Treg 
suppressive function at day 12 (S2), this increase did not 
reach similar levels to those obtained from Tregs expanded 
in the presence of rapamycin (1:1 ratio 60.5% ± 7.26 vs. 
88.2% ± 2.76, respectively; P = 0.0026; and 1:10 ratio 
42.0% ± 8.99 vs. 79.1% ± 3.90, respectively; P = 0.0016). 
Moreover, the increase in Treg suppressive function was 
not preserved by final harvest in the untreated cultures 
as compared to the rapamycin treated cultures (1:1 ratio 
25.2% ± 4.58 vs 84.8% ± 3.96, respectively; P = 0.0001; 
1:10 ratio 7.32% ± 2.32 vs 68.3 ± 6.85, respectively; P = 
0.0001) (Figure 4). These results further support the use 
of the rapamycin based GMP protocol in the expansion 
of autologous Tregs from ARC patients in view of the 
increased Treg suppressor function.
rapamycin stabilizes the treg population by 
preventing Il-17 production
One of the major concerns in Treg immunotherapy 
is the plasticity of Tregs and their conversion to cells 
producing inflammatory cytokines, when exposed to a 
pro-inflammatory environment [28, 29]. As such, freshly 
isolated and expanded Tregs were cultured for 5 days 
in the presence of Th17 skewing conditions and the 
percentage of IL-17+ cells (Figure 5A) and the production 
of IL-17 (Figure 5B) assessed by FACS and ELISA, 
respectively, in order to ascertain their stability. Our data 
clearly confirmed that over the 36-days culture period 
the presence of rapamycin resulted in the production of 
a stable population of Tregs with a reduced percentage of 
IL-17+ cells as compared to baseline, when exposed to a 
proinflammatory milieu (Mix 1: P = 0.0384; Mix 2: P = 
0.0446). Additionally, diminished IL-17 production was 
detected on analysis of culture supernatants, confirming 
the data obtained by intracellular staining (Mix 1: S1 
1965pg/ml ± 318 vs. final harvest 124pg/ml ± 34.5; P < 
0.0001; Mix 2: S1 1322pg/ml ± 347 vs. rapamycin at final 
harvest: 84.3pg/ml ± 35.3; P = 0.0027) (Figure 5A, 5B). 
Moreover, assessment of the percentage of IFNγ+ cells 
also clearly demonstrated that rapamycin resulted in a 
non-inflammatory Treg population with a reduction in the 
frequency of FOXP3+IFNγ+ cells by final harvest (Mix 1 
S1; 6.42% ± 0.915 vs. final harvest 2.54% ± 0.560; P = 
0.0023; Mix 2; S1 4.61% ± 0.698 vs. final harvest 2.82% 
Figure 4: Assessement of treg suppressive function. Representative histogram and graph from 9 ARC patients upon assessment 
of Treg suppressor function. The suppressive function of Tregs cultured ± rapamycin was assesed by CFSE dilution assay at day 0 and 
throughout the 36 day culture period. n.s.- not significant. *P < 0.05, ***P < 0.001. Data are represented as mean +/- SEM.
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± 0.688; P = 0.084) (Figure 5C). 
To further assess the susceptibility of Tregs to 
differentiate into Th17 cells the expression of CD161 
on the Tregs was investigated. Expression of CD161 by 
T cells has been reported as a marker for precursors of 
IL-17 producing T cells and in addition, characterises a 
population of Tregs with the propensity to produce IL-17, 
as shown by our group and others [30-33].
Our data showed that during the 36-day expansion 
period there was a decrease in the percentage of 
CD161+ Tregs (from 19.6% ± 2.42 to 1.48% ± 0.26; 
P < 0.0001) (Figure 5D). In parallel a decrease in the 
Figure 5: Intracellular expression of IL-17 and IFN-γ and production of IL-17 by ex vivo expanded tregs. A. Frequency 
of IL-17+ in CD4+CD25+FOXP3+ Tregs upon isolation and post culture in the presence of rapamycin (day 36) when exposed to two separate 
mixes of pro-inflammatory cytokines (Mix 1: IL-2, IL1β, IL-6 and TGF-β and Mix 2: IL-2, IL-21, IL-23 and TGF-). b. IL-17 (pg/ml) 
concentration in a 5-day culture supernatant of the rapamycin expanded Tregs in the presence of Mix1 and Mix2. c. Frequency of IFN-γ+ 
in CD4+CD25+FOXP3+ Tregs upon isolation and post ex vivo expansion in the presence of rapamycin (day 36) when exposed to Mix 1 and 
Mix 2. d. Gating strategy and Frequency of CD161+ Tregs throughout culture. Dot plot depicts expression of CD161 on CD4+CD25+ Tregs 
from a representative sample of 9 ARC patients. Graph shows the dynamics of CD161 expressing Tregs throughout culture. e. Gating 
strategy and Frequency of CCR6+CD161+ Tregs throughout culture. Dot plot of CD161+CCR6+ co-expression on CD4+CD25+ Tregs from a 
representative sample of 9 ARC patients and graph of percentage CD161+CCR6+ co-expression throughout culture. n.s.-not significant. *P 
< 0.05,**P < 0.01. ***P < 0.001. n = 9 ARC patients. Data are represented as mean +/- SEM.
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table 1A: clinical-grade tregs expanded in the clinical research Facility
          total cells x106
 s1 s2 s3 Final harvest
ARC 1 1.47 28 172 680
ARC 2 4 17.7 159 1250
ARC 3 5.5 41.3 397.6 2680
All final products reached above the numbers needed for the maximum dose of Treg injection planned (4.5x106) for the ThRIL 
trial; n = 3. Abbreviation: S, stimulation; S1, day 0; S2, day 12; S3, day 24; final, day 36
table 1b: treg manufacture in the clinical research Facility
test Specification Arc 1 Arc 2 Arc 3
 
 
Final 
harvest defrosting
Final 
harvest defrosting
Final 
harvest defrosting
Months post cryopreservation 3 3 3
Identity:
Positive for cd4 
cd25
FoXP3 YES YES YES YES YES YES
Purity:
≥ 60% of entire cell 
population cd4+ 
cd25+ FoXP3 93.9 89.1 88.8 92.6 84.9 97.0
Impurity:
≤ 10% CD8 0.36 1.14 0.43 0.5 1.95 0.6
≤100 beads per 
3x106 cells 75 - 23 - 45 -
Viability:
≥ 70% viability
91.0 93 97.3 85.0 96.5 84.0
recovery 
(live):
≥ 70%
- 95 - 80.0 - 114
Potency:
≥ 60% suppression
93.0 99 65.0 97.0 - 95.0
safety tests:
sterility-no growth No growth - No growth - No growth -
Endotoxin ≤175IU/
ml <5 IU/ml - <5 IU/ml - -
Mycoplasma-not 
detected not detected - not detected - -
All final products met the necessary release criteria on day 36 for their clinical application. After 3 months post 
cryopreservation cells maintained their phenotype and suppressive function. 
Abbreviation: ARC, alcohol related cirrhosis
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percentage of Tregs co-expressing CD161 and CCR6 
in rapamycin treated cultures as compared to baseline 
was also demonstrated (0.500 ± 0.107 vs 12.5% ± 1.75, 
respectively, P < 0.0001) (Figure 5E). 
tregs from Arc patients were enriched, 
expanded and cryopreserved in the clinical 
research Facility
To extend the Treg protocol from the laboratory 
to the GMP facility and validate the process for clinical 
use in ThRIL, 150ml of peripheral blood was obtained 
from three patients with ARC and Tregs isolated, using 
the CliniMACS Plus system and expanded in the BRC 
CRF, Guy’s Hospital. Comparison of the recovery of the 
isolated cells from ARC patients in the BRC CRF and the 
research laboratory revealed an initial lower recovery of 
cells, 3.68 ± 1.18 x106 vs. 7.14x106 ± 1.27, respectively 
(Figure 1A, Table 1A). Despite this, Tregs from patients 
were successfully expanded, reaching numbers well over 
the requirements of the ThRIL trial (Table 1A).
After ex vivo expansion, a comprehensive 
analysis of the Tregs was performed to ensure the final 
product satisfied the specified release criteria, essential 
for their clinical application (Supplementary Table 
4). At final harvest the mean percentage of cells with 
a CD4+CD25+FOXP3+ phenotype was 89.2% ± 2.61 
with 0.913% ± 0.591 CD8+ cells, with a mean viability 
of 94.9% ± 1.98. Evaluation of the potency of the final 
product showed the expansion of Tregs with suppressive 
ability >65% (Table 1B). 
Of note, however, ThRIL requires the final product 
to be injected 3 months post transplantation and therefore 
necessitates cryopreservation of these cells. Following 
cryopreservation >80% live cells were recovered and the 
results demonstrate that Tregs maintained their phenotype 
and function (Table 1B).
dIscussIon
One of the major drawbacks following liver 
transplantation is the requirement for lifelong treatment 
with immunosuppressants with their accompanying 
side effects and complications. This contributes to a 
disappointing 60% patient survival rate at 10 years after 
transplantation. In this regard, the use of cell-based 
therapies, harnessing the natural immunoregulatory 
properties of the immune system, is an emerging 
therapeutic option and Tregs have been recognized as ideal 
candidates in this endeavor. 
ThRIL is a pioneering two stage clinical trial 
investigating the use of autologous Treg immunotherapy 
as an individualised medicine to promote transplantation 
tolerance in liver transplantation. Stage I, prioritises the 
safety and tolerability of Treg immunotherapy with Treg 
efficacy assessed in Stage II whereby immunosuppression 
withdrawal will be attempted in transplant recipients who 
have received the highest tolerated dose of Tregs. 
To date studies aimed at withdrawing 
immunosuppression in liver transplant recipients early 
post transplantation have been largely unsuccessful [34] 
highlighting the need for an intervention, such as that 
proposed in ThRIL, to promote ‘tolerance’. 
Here, we outline the first account of the ex vivo 
expansion of Tregs from prospective liver transplant 
recipients at GMP standards. The data presented describes 
the clinical grade isolation strategy and demonstrates the 
feasibility of autologous Treg cell-based therapy in liver 
transplantation. 
We present data on the selection of a pure population 
of Tregs (CD4+CD25+ at S1: 77.7% ± 10.3), using a two-
step magnetic activated cell sorting (MACS) protocol. 
In two of the reported clinical trials [13, 16] a higher 
degree of Treg purity was attained using Treg isolation 
based on the combined expression of CD4+, CD25+, and 
low expression of CD127 molecules [22]. Whilst cell 
isolation based on a combination of these markers is 
highly effective, the lack of GMP cell sorter facilities in 
the UK makes this translationally unfeasible. In addition, 
Marek et al. showed that during the expansion process 
Tregs were “transforming” into effector/memory like cells 
and proposed that regardless of the phenotypic markers 
used for Treg isolation, the only variable to maintain 
Treg phenotype and function is to limit the duration of 
expansion to 2 weeks [35].
In support of this study, others have also shown that 
the large-scale manufacture of Tregs remains challenging, 
reporting that even when starting with a highly pure 
population of Tregs, repeated stimulation results in the loss 
of FOXP3 expression [21]. In the clinical trial conducted 
by Trzonkowski et al. a decrease in the percentage 
FOXP3+ cells after successive weekly stimulation was 
reported [13]. However, the disadvantage of limiting 
cultures to two rounds of stimulation became evident in 
the trial of Treg immunotherapy in Type 1 diabetes where 
the authors noted an insufficient Treg yield in four out of 
the ten patients [16].
We generated Tregs in concordance with the 
proposed GMP protocol, expanding these cells in vitro for 
36 days with three rounds of stimulation, in the presence 
of rapamycin. This resulted in the expansion of Tregs to 
numbers sufficient for administration of the maximum 
dose for the ThRIL trial. Despite the three rounds of 
stimulation, and contrary to the studies outlined above, 
FOXP3 expression was maintained in culture and the data 
clearly demonstrated that in the presence of rapamycin 
there was an increase in the percentage of FOXP3Hi Tregs 
and in the level of expression of FOXP3 at final harvest 
(Figure 3B, 3C). 
One of the concerns with the clinical translation 
of bead-separated Treg preparations is the presence 
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of ‘contaminating’ effector T cells. However, as has 
been reported previously [18], expansion of Tregs in 
the presence of rapamycin led to the enrichment of a 
Treg population with increased CD127lo and CTLA-
4 expression (Figure 3D, 3F), correlating with the 
pronounced increase in suppressive function (Figure 4). 
CTLA-4 has been recognized as an important regulatory 
marker expressed by Tregs and has been reported to play 
an important role in their suppressive function, through 
the internalization of co-stimulatory molecules on 
antigen presenting cells (APC) [23]. This has significant 
implications, concerning the clinical application of 
autologous patient derived Tregs in the setting of liver 
transplantation, whereby our protocol ensures the high 
expression of this key regulatory molecule.
Another major potential barrier to Treg therapy is the 
possibility that these cells may assume a pro-inflammatory 
phenotype. In this study, we provide further evidence to 
our published data where we report that conditioning of 
Tregs with rapamycin leads to the production of a stable, 
non-inflammatory Treg population due to the inhibition 
of IL-17 and IFN-γ production by Tregs in vitro in the 
presence of intense inflammatory conditions (Figure 5A, 
5B) [18, 36]. 
In line with this, a decrease in the percentage of 
cells co-expressing CD161 and CCR6 was demonstrated, 
confirming previous work [37]. Moreover, in view of 
the plasticity of Tregs, Kopft et al. studied the reciprocal 
differentiation of Tregs and Th17 cells and reported that 
rapamycin suppresses the differentiation of pathogenic 
Th17 cells [38]. As such, patients in the ThRIL study will 
be taking rapamycin by the time of Treg infusion. This 
adjunctive immunosuppression has the dual advantages of 
promoting Treg survival and stability by reducing the risk 
of the injected cells acquiring pro-inflammatory features. 
Furthermore there have been reports of the 
importance of epigenetic control of Foxp3 expression 
through the methylation of the Treg specific demethylated 
region (TSDR). Future research will be focused at 
understanding Treg commitment and epigenetic regulation 
of FOXP3 expression so that the mechanisms can be 
harnessed to stabilise the Tregs, of importance for their 
clinical application.
In addition to stability, therapeutic strategies 
using Tregs have to also take into account the need for 
appropriate tissue trafficking to enable contact with their 
target cells. The expression of the chemokine receptor, 
CXCR3, has been reported to mark subsets of T cells 
associated their migration to sites of inflammation [39]. 
Furthermore, in a murine model of T cell mediated liver 
injury, Lapierre et al. demonstrated the ability of CXCR3+ 
Tregs to migrate to the liver, in turn potentiating the 
effectiveness of Treg adoptive transfer [40]. The data 
presented here demonstrates the preservation of cells 
expressing CD62L and CXCR3, important for their 
passage to lymph nodes and the liver respectively (Figure 
3H).
Finally, we show that despite a lower recovery of 
isolated cells (Tables 1A & 1B), partly explained by the 
closed system of isolation procedure which involves a 
longer, more vigorous cell isolation procedure, adequate 
numbers of Tregs, that meet the trial release criteria, 
can be expanded in the BRC CRF at Guy’s Hospital and 
remain functional after freeze-thawing, a prerequisite 
precluding their clinical translation. 
Additionally, it is pertinent to note that initial 
confidence in adoptive Treg cell therapy as a self-sufficient 
entity, experimental data has shown that the efficacy of 
Treg therapy requires the setting of a favorable in vivo 
environment, supporting both the cell engraftment and 
the chance of inducing tolerance, such as transient host 
T cell depletion by immunosuppressive treatments 
[41, 42]. This highlights the importance of strategies to 
tailor immunosuppressive therapy to ensure the in vivo 
survival of the injected Tregs or enhance their longevity 
in vivo. In this regard the clinical protocol for ThRIL is 
based on a Treg supportive immunosuppressive regimen 
including the use anti-thymocyte globulin (ATG), to 
induce lymphopenia with a preferential preservation of 
Tregs [43]. Additionally to limit memory T cell expansion 
post ATG induction, patients are started on tacrolimus and 
prednisolone and a month prior Treg infusion maintained 
on low dose tacrolimus with the addition of rapamycin, 
to promote selective Treg expansion in vivo [44]. The 
intention behind this protocol: to create a tolerogenic 
milieu thus maximizing the potential efficacy of the 
exogenously administered Tregs through prolongation 
of their in vivo survival. It is also reassuring that these 
cells will be injected in a ‘Treg nurturing’ environment, 
centered on the inclusion of rapamycin, as compared 
to other immunosuppressants whose indiscriminant 
mechanism of action poses a threat to Treg survival. 
Thus, tailoring the immunosuppressive regimen 
along with the administration of ex vivo expanded Tregs 
may potentially maintain post liver transplant tolerance, 
accomplishing the ultimate aim of Treg immunotherapy 
trials in this setting.
Presently, the first two patient recruited into the 
ThRIL trial have received the first Treg injection, with 
no reported toxicity to date. The near future will now see 
the reporting of this clinical trial along with the much 
anticipated immunomontoring data, informing the in vivo 
dynamics of the cells expanded. There is no question that 
the information gleaned from the ThRIL trial will serve 
as to guide the transition of Tregs as a viable therapeutic 
option in liver transplant recipients. 
Additionally, with the advent of GMP-compliant 
FACS sorting there will be developments in the current 
GMP protocol for the manufacture of the final cell 
product with a focus on the optimal Treg subset with 
potent suppressive function, specificity, and those that are 
epigenetically stable. 
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MAterIAl And Methods
Participant selection criteria
150ml of peripheral blood was obtained from 12 
patients with alcohol related cirrhosis (ARC), awaiting 
transplantation. Patient selection was based on the 
inclusion criteria in accordance with the ThRIL clinical 
protocol (NCT02166177) (Supplementary Table 1 and 
Table 2). As outlined by the UK transplant registry 
http://www.odt.nhs.uk/uk-transplant-registry/ cirrhosis 
secondary to alcohol is one of the leading indications for 
liver transplantation in the UK and as such this cohort of 
patients form the majority of patients recruited into the 
ThRIL trial. 
Peripheral blood was obtained from 9 age and sex 
matched healthy controls (HCs). All blood samples were 
handled and disposed of in concordance with Human 
Tissue Act 2008. Human studies were conducted in 
accordance with the Declaration of Helsinki and approved 
by the Institutional Review Board (09/H0707/86).
treg isolation
In the laboratory, peripheral blood mononuclear 
cells (PBMC) were isolated from patients and HCs by 
lymphocyte (PAA, Pasching, Austria) density gradient 
centrifugation and depleted for CD8+ cells followed 
by enrichment of CD25+ T cells using magnetic beads 
(Miltenyi Biotec, Woking, UK) and as previously reported 
[17]. All reagents and consumables used were of clinical 
GMP grade. 
In the BRC CRF, blood volume was reduced, using 
the Sepax® 2 device (Biosafe) prior to Treg isolation. 
Tregs were purified using a combination of CD8+ 
reduction (CliniMACS CD8 reagent, Miltenyi Biotec, 
Woking, UK) and enrichment steps for CD25+ cells 
(CliniMACS CD25 reagent, Miltenyi Biotec), using the 
automated CliniMACS® Plus System (Miltenyi Biotec) in 
the BRC CRF at Guy’s Hospital. All processing steps were 
performed in closed systems, using single use tubing sets. 
expansion of treg lines
Isolated cells were plated at 1x106/ml cell and 
activated with anti-CD3/CD28 coated beads (Invitrogen, 
Paisley, UK; Miltenyi Biotech) at a 2:1 bead:cell ratio. 
Cells were expanded in culture media X-vivo 15 (Lonza, 
Basel, Switzerland) 5% human AB serum (HS) (Biosera, 
Ringer, UK; Lonza) containing rapamycin (100 nM) 
(Rapamune®, Wyeth, USA) for 36 days. IL-2 (500 IU/
ml, Proleukin®, Novartis, UK) was added at day 4 post-
activation and replenished every 2 days. Cells were 
restimulated every 10-12 days. Beads were magnetically 
removed and the cells washed in PBS. This process was 
repeated to ensure bead removal following which, fresh 
beads, rapamycin and IL-2 were added. Expanded cells 
were used for further analysis at each time of restimulation 
up until day 36 of expansion.
In the BRC CRF, under GMP conditions, enriched 
cells were seeded in MACS® GMP Cell Expansion 
Bags at 0.5×106 cells/mL in TexMACS™ GMP Medium 
(Miltenyi Biotec) supplemented with 5% human AB 
serum (Seralab, UK), containing 100 nM rapamycin 
(Rapamune®, Pfizer) and activated with anti-CD3/CD28-
coated beads (4:1 bead:cell ratio, MACS GMP ExpAct 
Treg Kit, Miltenyi Biotec). Human recombinant IL-2 (500 
IU/mL; Proleukin®, Novartis) was added at day 4-6 and 
replenished every 2-3 days. The cells were rested 4 days 
before restimulation. Stimulation occurred on days 12 and 
24, during which time cells were pooled, fresh beads (1:1), 
rapamycin, and IL-2 added. At final harvest, the pooled 
cells were processed on the CliniMACS Plus Instrument 
using a pre-set depletion program to remove the ExpAct 
Treg expansion beads. A sample of the cells was assessed 
for safety and functional analysis. 
Flow cytometry
Flow cytometric analysis was performed on freshly 
isolated and expanded Tregs using the BD FACSCanto™ 
cell analyzer (BD Bioscience, Oxford, UK) and analysed 
using FlowJo software (TreeStarInc, OR, USA). In 
short, cells were washed and stained with the listed 
mAbs in the Supplementary Table 3 for 30 min at 4°C. 
Appropriate isotype control antibodies were used for each 
sample. Following staining, cells were examined by flow 
cytometry. 
Intracellular staining for FOXP3 was performed 
in accordance with the manufacturer’s protocol 
(eBioscience). Expression levels of and IL-17 was 
assessed after activation of cells with phorbol myristate 
acetate (PMA, 5ng/ml, Sigma Aldrich, St Luis, MO, 
USA), Ionomycin (1µg/ml, Sigma Aldrich, St Luis, MO, 
USA) and Monensin (2µM, eBioscience, San Diego, CA, 
USA) for 4 hours. Subsequently, the intracellular staining 
for IL-17 was performed according to the manufacturer’s 
protocol.
In the BRC CRF, flow cytometry, using CD4-PerCP/
Cy™5.5, CD-25PE, CD8-APC was carried out on the BD 
FACSCanto™ cell analyzer (BD Bioscience). Intracellular 
staining for FOXP3-FITC was performed, as above, in 
accordance with manufacturer’s protocol (eBioscience). 
Appropriate isotype controls and Fluorescence minus one 
controls were used to assign gates and analysis carried out, 
using the FlowJo software.
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suppression assay
Responder CD4+CD25- T cells were obtained from 
PBMCs by negative selection using unconjugated anti-
CD8 (6μL/108cells), anti-CD33 (3μL/108cells) (both 
Caltag, California, USA), anti-CD14 (7μL/108cells), anti-
CD16 (7μL/108cells), anti-CD19 (6μL/108cells), anti-
CD56 (3μL/108cells), anti-γδ TCR (7μL/108cells) and 
glycophorin CD235a (all Diaclone, Gen-probe, San Diego, 
USA) antibodies with pan-IgG microbeads and anti-CD25 
microbeads (both Invitrogen, Paisley, UK)
Aliquots of the CD4+CD25- cells were cryopreserved 
and used as allogeneic responder cells in suppression 
assays.
Cryopreserved responder CD4+CD25- T cells 
(Teff) were thawed and labelled with 2.5 nM the 
carboxyfluorescein succinimidyl ester (CFSE) (Molecular 
Probes, Carlsbad, CA, USA). Responder purity was >95% 
(Supplementary Figure 4). 1x105/well of responder T cells 
were co-cultured at different ratios (Treg: Teff = 1:1, 1:5 
and 1:10) with Tregs in X-Vivo 15 medium supplemented 
with 5% HS and activated by anti-CD3/CD28-coated 
beads (Invitrogen, Paisley, UK) in U-bottom 96-well 
plates. Cells were incubated at 37°C, 5% CO2 for 5 days. 
After harvest, proliferation of CFSE-labelled responder 
cells was determined by flow cytometry (FACSCalibur 
or on LSRFortessa™ cell analyzer (BD Bioscience) and 
analyzed with FlowJo software (Tree Star Inc, OR, USA). 
The suppressive ability of Treg lines was assessed as the 
percentage decrease of Teff proliferation in the presence 
of Tregs. The calculation was based on the proliferation of 
responder T cells alone compared with the proliferation of 
cultures also containing Treg cells.
Treg culture in the presence of pro-inflammatory 
cytokines
Freshly isolated, untreated and rapamycin treated 
CD4+CD25+ T cells (5x105) were activated with anti-CD3/
CD28 coated beads at 1:1 bead:cell ratio and cultured 
for 5 days in the presence of pro-inflammatory cytokine 
cocktails: Mix 1: IL-2 (10 IU/ml), IL1β (10ng/ml, R&D 
Systems, Minneapolis, MN, USA), IL-6 (4ng/ml, R&D 
Systems, Minneapolis, MN, USA) and TGF-β (5ng/ml, 
R&D Systems, Minneapolis, MN, USA). Mix 2: IL-2 
(10 IU/ml), IL-21 (25ng/ml, Cell Sciences, Canton, MA, 
USA), IL-23 (25ng/ml, R&D Systems, Minneapolis, MN, 
USA) and TGF-β (5ng/ml, R&D Systems, Minneapolis, 
MN, USA). Cells cultured in complete medium 
supplemented with IL-2 (10 IU/ml) were used as controls 
to ensure their survival throughout the 5-day stability 
assay.
At the end of the culture cells were harvested, 
activation beads removed by magnetic adherence and 
analysed for IL-17 and IFN-γ expression by intracellular 
staining. IL-17 in supernatants was analysed by an indirect 
sandwich ELISA. 
elIsA
ELISA for human IL-17 was carried out using the 
Duo-Set ELISA kit from R&D (Abingdon, UK) according 
to manufacturer’s instructions 
cryopreservation of the expanded tregs in the 
crF
After final harvest, all batches were assessed against 
the set release criteria for the ThRIL trial (Supplementary 
Table 4) and subsequently cryopreserved. In brief, Treg 
numbers equivalent to doses for the ThRIL trial were 
resuspended in 2.1ml of CryoStor® CS10 freezing media, 
transferred to a CellSeal® Cryovial and placed in a 
controlled rate freezer before transfer to liquid nitrogen 
(vapor phase) for long-term storage. 
In order to assess the recovery of the cryopreserved 
product and the effect of cryopreservation on the biology 
and function of the final product, cells were thawed, 
diluted in 5% human serum albumin, and the viability and 
suppressive function of the cryopreserved product was 
assessed. 
statistical analysis
Statistical analysis was carried out on GraphPad 
Prism 5.0c (GraphPad software Inc. CA, USA). Parametric 
and nonparametric data were expressed as mean ± standard 
error and median where appropriate. For comparison of 
parametric data, paired and unpaired students t-tests were 
used. Statistical significance was set at P < 0.05.
*P< 0.05, ** P< 0.01 and *** P< 0.001
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